| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Allophycocyanin | IC1195A | |||
| Biotin | BAM1195 | |||
| NL493 | NL1195G | |||
| NL557 | NL1195R | |||
| NL637 | NL1195V | |||
| PerCP (Peridinin-chlorophyll Protein Complex) | IC1195C | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | IC1195C | |||
| Carrier Free | IC1195A | |||
| Carrier Free | NL1195R | |||
| Carrier Free | NL1195G | |||
| Carrier Free | NL1195V | |||
| Carrier Free | MAB1195-SP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 488 | IC2085G | |||
| Allophycocyanin | IC2085A | |||
| Biotin | BAF2085 | |||
| NL557 | NL2085R | |||
| Phycoerythrin | IC2085P | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | IC2085P | |||
| Carrier Free | IC2085A | |||
| Carrier Free | IC2085G | |||
| Carrier Free | NL2085R | |||
| Carrier Free | AF2085-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF3626-SP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor 350 | IC835U-100UG | |||
| Alexa Fluor 405 | IC835V-100UG | |||
| Alexa Fluor 488 | IC835G-025 | |||
| Alexa Fluor 488 | IC835G-100 | |||
| Alexa Fluor 594 | IC835T-100UG | |||
| Alexa Fluor 647 | IC835R-100UG | |||
| Alexa Fluor 700 | IC835N-100UG | |||
| Alexa Fluor 750 | IC835S-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB835-SP | |||
| Carrier Free | IC835G-025 | |||
| Carrier Free | IC835G-100 | |||
| Carrier Free | IC835T-100UG | |||
| Carrier Free | IC835S-100UG | |||
| Carrier Free | IC835U-100UG | |||
| Carrier Free | IC835V-100UG | |||
| Carrier Free | IC835N-100UG | |||
| Carrier Free | IC835R-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF-317-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | IC1368G | |||
| Carrier Free | IC1368P | |||
| Carrier Free | MAB1368-SP | |||
| Carrier Free | IC1368V-100UG | |||
| Carrier Free | IC1368U-100UG | |||
| Carrier Free | IC1368T-100UG | |||
| Carrier Free | IC1368S-100UG | |||
| Carrier Free | IC1368R-100UG | |||
| Carrier Free | IC1368N-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF457-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | IC7578P | |||
| Carrier Free | IC7578A | |||
| Carrier Free | IC7578G | |||
| Carrier Free | IC7578N | |||
| Carrier Free | MAB7578-SP | |||
| Carrier Free | IC7578U-100UG | |||
| Carrier Free | IC7578T-100UG | |||
| Carrier Free | IC7578V-100UG | |||
| Carrier Free | IC7578S-100UG | |||
| Carrier Free | IC7578R-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | IC1455P | |||
| Carrier Free | IC1455G | |||
| Carrier Free | MAB1455-SP | |||
| Carrier Free | IC1455V-100UG | |||
| Carrier Free | IC1455U-100UG | |||
| Carrier Free | IC1455T-100UG | |||
| Carrier Free | IC1455S-100UG | |||
| Carrier Free | IC1455R-100UG | |||
| Carrier Free | IC1455N-100UG | |||
| Carrier Free | IC1455A-100UG | |||
![Soluble factors increase the numbers of Hes3+ cells in the adult rat hippocampus.(a) Treatment with the soluble factors induced a powerful increase in the number of Sox2+ cells in the hilus [Quantifications are from images taken from the tip of the hilus to approximately 1,300 micrometers towards the CA3 region – representative images are shown. Staining for the young neuron marker doublecortin (DCX) helps to visualize the subgranular zone]. (b) The same treatment also induced an increase in the numbers of Hes3+ cells in the hilus. (c) Sox2+ cells inside the hilus co-expressed Hes3; in contrast, Sox2+ cells in the subgranular zone did not co-express Hes3. (d,e) Quantification graphs of the increases in Sox2+ and Hes3+ cell numbers in the hilus (p0.05; *, p0.05, #, p<0.05 compared to fluoxetine. Scale bar: 50 µm. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24598761), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/mab2018_human-mouse-rat-sox2-mab-clone-245610-41202410333037.jpg)
![CXCR4 and CXCL12 expression in DLBCL. (a) Expression analysis of CXCR4 and CXCL12 in non-neoplastic control germinal center B cells (GC-B) and diffuse large B cell lymphoma cells (DLBCL) consisting of DLBCL-NGCB and DLCBL-GCB, by RQ-PCR. GCB-DLBCL were further subdivided into primary (DLBCL-pGCB) and transformed DLBCL (DLBCL-pGCB) originating from follicular lymphoma. (b) Expression analysis of CXCR4 and CXCL12 in DLBCL samples with early (stage 1) and advanced stage (stage 2–4) (left graphs) and DLBCL samples with and without bone marrow infiltration (right graphs) by RQ-PCR. (c) Probability of 5-year-survival in DLBCL patients (our cohort left panel and the cohort of Lenz et al. right [20]) stratified by the third quartile of CXCR4 expression, respectively. (d) Representative immunohistochemical stains of CXCR4 (I–III) and CXCL12 (IV–VI) on DLBCL samples (magnification 20×). mRNA expression levels were calculated as a relative expression in comparison to the GC-B cells. All images were captured using an Olympus BX51 microscope and an Olympus E-330 camera. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31554271), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/mab350_human-mouse-cxcl12-sdf-1-mab-clone-79018-41202410331984.jpg)
![Apoptotic markers in PFII treated NHDFs.(A–C) [Ca2+]i fluorescence visualizations in cells as revealed by using an LSCM with fluorescent probe Fluo3/AM, scale bar - 100 µm. (D–F) Externalized phosphatidylserine by annexin V-fluorescein binding after PFII treatment, scale bar - 100 µm. Third (G–I) and fourth (J–L) panels show actin cytoskeletal organization and caspase-3 activation. Scale bar - 50 µm. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0057991), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/mab835_human-mouse-cleaved-caspase-3-asp175-mab-clone-269518-4120241033306.jpg)
![Apoptotic markers in PFII treated NHDFs.(A–C) [Ca2+]i fluorescence visualizations in cells as revealed by using an LSCM with fluorescent probe Fluo3/AM, scale bar - 100 µm. (D–F) Externalized phosphatidylserine by annexin V-fluorescein binding after PFII treatment, scale bar - 100 µm. Third (G–I) and fourth (J–L) panels show actin cytoskeletal organization and caspase-3 activation. Scale bar - 50 µm. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0057991), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/mab835_human-mouse-cleaved-caspase-3-asp175-mab-clone-269518-41202410331936.jpg)
![Apoptotic markers in PFII treated NHDFs.(A–C) [Ca2+]i fluorescence visualizations in cells as revealed by using an LSCM with fluorescent probe Fluo3/AM, scale bar - 100 µm. (D–F) Externalized phosphatidylserine by annexin V-fluorescein binding after PFII treatment, scale bar - 100 µm. Third (G–I) and fourth (J–L) panels show actin cytoskeletal organization and caspase-3 activation. Scale bar - 50 µm. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0057991), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/mab835_human-mouse-cleaved-caspase-3-asp175-mab-clone-269518-41202410325552.jpg)
